Drug Profile
MP 2269
Latest Information Update: 20 Jul 2011
Price :
$50
*
At a glance
- Originator Mallinckrodt Medical
- Class Gadolinium-containing contrast agents; Small molecules
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 20 Jul 2011 Discontinued - Preclinical for Vascular disorders in USA (IV)
- 01 Nov 2000 Mallinckrodt has been acquired by Tyco International
- 26 Jan 2000 Preclinical development for Vascular disorders (diagnosis) in USA (IV)